- Home
- CUBI vs TARS Comparison
CUBI vs TARS Comparison
Compare CUBI & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUBI
- TARS
- Stock Information
- Founded
- CUBI 1994
- TARS 2016
- Country
- CUBI United States
- TARS United States
- Employees
- CUBI N/A
- TARS N/A
- Industry
- CUBI Major Banks
- TARS Medicinal Chemicals and Botanical Products
- Sector
- CUBI Finance
- TARS Health Care
- Exchange
- CUBI Nasdaq
- TARS Nasdaq
- Market Cap
- CUBI 1.9B
- TARS 1.7B
- IPO Year
- CUBI 2012
- TARS 2020
- Fundamental
- Price
- CUBI $66.21
- TARS $51.82
- Analyst Decision
- CUBI Buy
- TARS Strong Buy
- Analyst Count
- CUBI 8
- TARS 7
- Target Price
- CUBI $69.25
- TARS $67.14
- AVG Volume (30 Days)
- CUBI 343.7K
- TARS 662.2K
- Earning Date
- CUBI 07-24-2025
- TARS 08-06-2025
- Dividend Yield
- CUBI N/A
- TARS N/A
- EPS Growth
- CUBI N/A
- TARS N/A
- EPS
- CUBI 4.05
- TARS N/A
- Revenue
- CUBI $596,459,000.00
- TARS $295,521,000.00
- Revenue This Year
- CUBI $15.74
- TARS $122.94
- Revenue Next Year
- CUBI $8.38
- TARS $44.14
- P/E Ratio
- CUBI $15.49
- TARS N/A
- Revenue Growth
- CUBI N/A
- TARS 254.45
- 52 Week Low
- CUBI $40.75
- TARS $24.95
- 52 Week High
- CUBI $67.19
- TARS $57.28
- Technical
- Relative Strength Index (RSI)
- CUBI 63.16
- TARS 74.43
- Support Level
- CUBI $60.95
- TARS $40.55
- Resistance Level
- CUBI $63.43
- TARS $42.11
- Average True Range (ATR)
- CUBI 1.78
- TARS 1.94
- MACD
- CUBI -0.07
- TARS 1.20
- Stochastic Oscillator
- CUBI 86.07
- TARS 96.24
About CUBI Customers Bancorp Inc
Customers Bancorp Inc is a bank holding company engaged in banking activities. It provides financial products and services to small and middle-market businesses, not-for-profits, and consumers. The company operates in Lending Activities, Commercial Lending, Consumer Lending, Private Banking, Deposit Products, Other Funding Sources and Financial Products and Services. The majority of revenue is derived from commercial lending.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.